bpc-157 gut health benefits evidence How Peptide Therapy Supports Recovery & Wellness Benefits of BPC-157 for Gut

GLOW Peptide Regulatory Status As of June 2026, none of the three GLOW compounds (BPC-157, TB-500, GHK-Cu) are FDA-approved for injectable human use

Minori Koga for experimental support and discussions

3.2 Annual comparison of PEDs samples (20202024) The numbers of the three types of samples provided for each year are summarized in Figure 2

What the Evidence Does NOT Show Because the marketing around these compounds is expansive, it is worth stating explicitly what the published record does not establish: It does not show that cagrilintide is superior, equal, or inferior to tirzepatide no head-to-head trial exists, so any ranking is cross-trial inference